Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
加利福尼亚州雷德伍德城，2024年11月27日（GLOBE NEWSWIRE）——开发治疗罕见疾病的新疗法的临床阶段生物制药公司索理诺治疗公司（“Soleno”）（纳斯达克股票代码：SLNO）今天宣布，管理层将在2024年12月5日星期四上午9点参加派珀·桑德勒第36届年度医疗保健会议的炉边谈话东部时间。
A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company's website at .
公司网站的 “投资者” 栏目将提供网络直播和炉边谈话的重播。
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit .
关于 Soleno Therapeutics, Inc.
Soleno专注于治疗罕见疾病的新疗法的开发和商业化。其主要候选药物DCCR（二氮氧化胆碱）缓释片剂（一种用于治疗普拉德威利综合征（PWS）的每日一次的口服片剂，目前正在接受美国食品药品管理局的审查，并已获得优先审评。欲了解更多信息，请访问。
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
公司联系人：
布莱恩·里奇
LifeSCI 顾问有限责任公司
212-915-2578
